**Scientific Research NMSC: running study**

|  |  |
| --- | --- |
| **Title study** | **A prospective, multicentre, observational post-authorization safety study to evaluate the long term safety profile of Lemtrada (Alemtuzumab) treatment in patients with RRMS.** |
| **Acronym** (if applicable) | **PASS** |
| **Summary / abstract** **(max 200 words)** | **The overall goal of the study is to better characterize the long-term safety profile of Lemtrada treatment in RRMS and to determine the incidence of adverse events of special interest.****Worldwide : 3.000 patients included, for Belgium : 115 patients included** |
| **Kind of study** | **multicenter** |
| **Principal Investigator/ Supervisor***(name + affiliation)* | **Prof Dr D’haeseleer** |
| **Local supervisor (NMSC)** |  |
| **Duration of the study***(months/years)*  | **5 years** |
| **Start date** | **2015** |
| **Anticipated end date** | **2022** |
| **Possibility to participate** | **No participation possible** |